Study of new drug combination for advanced prostate cancer
Part of Cancer clinical trials.
This trial tests a new drug called dalpiciclib combined with standard hormone therapy (abiraterone and prednisone) for men with prostate cancer that has spread and is hormone-sensitive. The goal is to see if adding the new drug helps control the cancer better than the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have been diagnosed with prostate adenocarcinoma (a common type of prostate cancer).
- Your cancer has spread to other parts of the body and is considered high-volume.
- You have not had treatment for prostate cancer before, except hormone therapy for up to 3 months, and you are still on that therapy.
- You are in good physical condition (able to do normal activities).
- You can swallow pills and do not have severe diarrhea or bowel blockage.
- You do not have serious lung disease like interstitial pneumonia or tumors in the brain.
- You have not used certain other prostate cancer drugs or therapies in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications (darxiciclib and abiraterone) for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It may help if you have already tried one newer hormone therapy and are looking for another option.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
This trial tests a new combination of two drugs (dalpiciclib and an HDAC inhibitor) for people with hormone receptor-positive, HER2-negative advanced breast cancer that has progressed after a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Hear when a new High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.